Evommune (EVMN) Current Assets (2024 - 2026)

Evommune (EVMN) has 3 years of Current Assets data on file, last reported at $215.9 million in Q1 2026.

• Quarterly Current Assets changed N/A year-over-year to $215.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $215.9 million (changed N/A YoY) and the FY2025 annual result came in at $153.5 million, up 107.44% from the prior year.
• Current Assets grew to $215.9 million in Q1 2026 per EVMN's latest filing, from $153.5 million in the prior quarter.
• Across five years, Current Assets topped out at $215.9 million in Q1 2026 and bottomed at $74.0 million in Q4 2024.
• The 3-year median for Current Assets is $117.7 million (2025), against an average of $131.3 million.
• Peak annual rise in Current Assets reached 107.44% in 2025, while the deepest fall reached 107.44% in 2025.
• Tracing EVMN's Current Assets over 3 years: stood at $74.0 million in 2024, then soared by 107.44% to $153.5 million in 2025, then jumped by 40.64% to $215.9 million in 2026.
• Per Business Quant, the three latest EVMN Current Assets figures stand at $215.9 million (Q1 2026), $153.5 million (Q4 2025), and $81.9 million (Q3 2025).

Peer Comparison